Focused On-demand Library for Platelet-derived growth factor subunit A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P04085

UPID:

PDGFA_HUMAN

Alternative names:

PDGF-1; Platelet-derived growth factor A chain; Platelet-derived growth factor alpha polypeptide

Alternative UPACC:

P04085; B5BU73

Background:

Platelet-derived growth factor subunit A (PDGF-A), also known as PDGF-1, plays a pivotal role in embryonic development, cell proliferation, migration, survival, and chemotaxis. It is a potent mitogen for mesenchymal cells and is essential for normal lung, gastrointestinal tract development, Leydig cell and spermatogenesis, oligodendrocyte development, and myelination in the spinal cord and cerebellum. PDGF-A's role in wound healing underscores its importance in tissue regeneration.

Therapeutic significance:

Understanding the role of Platelet-derived growth factor subunit A could open doors to potential therapeutic strategies, particularly in regenerative medicine and tissue repair. Its critical functions in cell proliferation and wound healing highlight its potential as a target for developing treatments for various conditions related to abnormal tissue growth and repair.